Systemic Sclerosis

137

Pipeline Programs↗

36

Active Trials↗

63

Companies Involved↗

Systemic Sclerosis is a highly competitive landscape with 137 programs across 63 companies. The most active players are Takeda, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Arog Pharmaceuticals, Inc.. 6 therapies are approved with 23 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

76/100

Pipeline Velocity

32/100

Mech. Concentration

8/100

Completion Rate

71/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Takeda

2 programs

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

1 program

Arog Pharmaceuticals, Inc.

1 program

Shanghai Ming Ju Biotechnology Co., Ltd.

1 program

Amphastar Pharmaceuticals, Inc.

1 program

AstraZeneca

2 programs

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

108 of 140 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 140 classified programs, each share of the total. Modality classified for 95% of 166 pipeline programs.

Analysis

Trial Status

159

clinical trials

Completed77 · 48%

Recruiting20 · 13%

Terminated20 · 13%

Unknown status14 · 9%

Not yet recruiting12 · 8%

Withdrawn9 · 6%

Other7 · 4%

Clinical Trials

Trial Activity

159 trials

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06375005·38 enrolled

Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04789850·74 enrolled

Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis

Recruiting·CCytori Therapeutics·N/A·NCT07360808·48 enrolled

Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis

Recruiting·TTopadur Pharma AG·Phase 2·NCT06954597·15 enrolled

The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting·PPeking University Third Hospital·Phase 4·NCT06546540·20 enrolled

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Recruiting·HHospital for Special Surgery, New York·Phase 2·NCT03844061·30 enrolled

Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06792344·12 enrolled

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Recruiting·—·Phase 2·NCT03630211·8 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05016804·20 enrolled

TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

Recruiting·—·Phase 1·NCT04380831·15 enrolled

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Recruiting·ZZura Bio Inc·Phase 2·NCT06843239·80 enrolled

Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

Recruiting·—·Phase 1·NCT06414135·6 enrolled

Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre

Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT04265144·500 enrolled

RY_SW01 Cell Injection Therapy in Systemic Sclerosis

Recruiting·—·Phase 1/2·NCT06058091·81 enrolled

Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis

Recruiting·UUMC Utrecht·Phase 1/2·NCT03211793·20 enrolled

Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)